Table 2 Association between ANK2 mRNA expression and clinical characteristics in LUAD
Characteristic | Low expression of ANK2 | High expression of ANK2 | P |
|---|---|---|---|
n | 267 | 268 | |
T stage, n (%) | < 0.001 | ||
T1 | 66 (24.8%) | 109 (41%) | |
T2 | 157 (59%) | 132 (49.6%) | |
T3 | 30 (11.3%) | 19 (7.1%) | |
T4 | 13 (4.9%) | 6 (2.3%) | |
N stage, n (%) | 0.025 | ||
N0 | 162 (61.6%) | 186 (72.7%) | |
N1 | 53 (20.2%) | 42 (16.4%) | |
N2 | 47 (17.9%) | 27 (10.5%) | |
N3 | 1 (0.4%) | 1 (0.4%) | |
M stage, n (%) | 0.357 | ||
M0 | 189 (92.2%) | 172 (95%) | |
M1 | 16 (7.8%) | 9 (5%) | |
Pathologic stage, n (%) | 0.015 | ||
Stage I | 132 (49.8%) | 162 (61.8%) | |
Stage II | 64 (24.2%) | 59 (22.5%) | |
Stage III | 53 (20%) | 31 (11.8%) | |
Stage IV | 16 (6%) | 10 (3.8%) | |
Gender, n (%) | 0.280 | ||
Female | 136 (50.9%) | 150 (56%) | |
Male | 131 (49.1%) | 118 (44%) | |
Age, n (%) | 0.187 | ||
< = 65 | 135 (52.5%) | 120 (46.3%) | |
> 65 | 122 (47.5%) | 139 (53.7%) | |
Smoker, n (%) | 0.630 | ||
No | 35 (13.5%) | 40 (15.3%) | |
Yes | 225 (86.5%) | 221 (84.7%) | |
Primary therapy outcome, n (%) | 0.544 | ||
PD | 37 (17.2%) | 34 (14.7%) | |
SD | 20 (9.3%) | 17 (7.4%) | |
PR | 4 (1.9%) | 2 (0.9%) | |
CR | 154 (71.6%) | 178 (77.1%) | |
OS event, n (%) | 0.003 | ||
Alive | 154 (57.7%) | 189 (70.5%) | |
Dead | 113 (42.3%) | 79 (29.5%) |